Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults
- 1 November 2001
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 15 (16), 2137-2147
- https://doi.org/10.1097/00002030-200111090-00009
Abstract
Treatment of latent infection is needed to protect HIV-infected individuals against tuberculosis. A previous report addressed short-term efficacy of three regimens in HIV-infected adults. We now report on long-term efficacy of the study regimens. Three daily self-administered regimens were compared in a randomized placebo-controlled trial in 2736 purified protein derivative (PPD)-positive and anergic HIV-infected adults. PPD-positive subjects were treated with isoniazid (INH) for 6 months (6H), INH plus rifampicin for 3 months (3HR), INH plus rifampicin and pyrazinamide for 3 months (3HRZ), or placebo for 6 months. Anergic subjects were randomized to 6H or placebo. 6H initially protected against tuberculosis in PPD-positive individuals; however, benefit was lost within the first year of treatment. Sustained benefit was observed in persons receiving 3HR and 3HRZ. In a Cox regression analysis, the adjusted relative risk for tuberculosis compared with placebo was 0.67 [95% confidence interval (CI), 0.42–1.07] for 6H, 0.49 (95% CI, 0.29–0.82) for 3HR, and 0.41 (95% CI, 0.22-0.76) for 3HRZ. When the rifampicin-containing regimens were combined, the adjusted relative risk for tuberculosis compared with placebo was 0.46 (95% CI, 0.29–0.71). Among anergic subjects, a modest degree of protection with 6H was present (adjusted relative risk, 0.61; 95% CI, 0.32–1.16). Treatment of latent tuberculosis infection had no effect on mortality. Six months of INH provided short-term protection against tuberculosis in PPD-positive HIV-infected adults. Three month regimens including INH plus rifampicin or INH, rifampicin and pyrazinamide provided sustained protection for up to 3 years.Keywords
This publication has 25 references indexed in Scilit:
- Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in UgandaAIDS, 2000
- Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected PersonsAn International Randomized TrialJAMA, 2000
- A Prospective Study of Tuberculosis and HIV Disease ProgressionJAIDS Journal of Acquired Immune Deficiency Syndromes, 1998
- Twice weekly tuberculosis preventive therapy in HIV infection in ZambiaAIDS, 1998
- The In Vitro Induction of Human Immunodeficiency Virus (HIV) Replication in Purified Protein Derivative‐Positive HIV‐Infected Persons by Recall Antigen Response toMycobacterium tuberculosisIs the Result of a Balance of the Effects of Endogenous Interleukin‐2 and Proinflammatory and Antiinflammatory CytokinesThe Journal of Infectious Diseases, 1998
- Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infectionThe Lancet, 1998
- A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1997
- A Controlled Trial of Isoniazid in Persons with Anergy and Human Immunodeficiency Virus Infection Who Are at High Risk for TuberculosisNew England Journal of Medicine, 1997
- Isoniazid preventive therapy for tuberculosis in HIV-1-infected adultsAIDS, 1997
- Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infectionThe Lancet, 1993